About: Alfuzosin

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Alfuzosin Goto Sponge NotDistinct Permalink

An Entity of Type : http://linked.opendata.cz/ontology/drugbank/Drug, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	http://linked.opendata.cz/ontology/drugbank/Drug
http://linked.open...gbank/description	Alfuzosin (INN, provided as the hydrochloride salt) is an alpha-adrenergic blocker used to treat benign prostatic hyperplasia (BPH). It works by relaxing the muscles in the prostate and bladder neck, making it easier to urinate. [Wikipedia] (en)
http://linked.open...y/drugbank/dosage	http://linked.opendata.cz/resource/drugbank/dosage/271B5CB2-363D-11E5-9242-09173F13E4C5 http://linked.opendata.cz/resource/drugbank/dosage/271B5CB3-363D-11E5-9242-09173F13E4C5 http://linked.opendata.cz/resource/drugbank/dosage/271B5CB4-363D-11E5-9242-09173F13E4C5 http://linked.opendata.cz/resource/drugbank/dosage/271B5CB5-363D-11E5-9242-09173F13E4C5
http://linked.open...generalReferences	# McKeage K, Plosker GL: Alfuzosin: a review of the therapeutic use of the prolonged-release formulation given once daily in the management of benign prostatic hyperplasia. Drugs. 2002;62(4):633-53. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11893233 # Wilde MI, Fitton A, McTavish D: Alfuzosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia. Drugs. 1993 Mar;45(3):410-29. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/7682910 # Andersson KE, Lepor H, Wyllie MG: Prostatic alpha 1-adrenoceptors and uroselectivity. Prostate. 1997 Feb 15;30(3):202-15. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/9122046 # Elhilali MM: Alfuzosin: an alpha1-receptor blocker for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. Expert Opin Pharmacother. 2006 Apr;7(5):583-96. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16553574 # Roehrborn CG: Alfuzosin: overview of pharmacokinetics, safety, and efficacy of a clinically uroselective alpha-blocker. Urology. 2001 Dec;58(6 Suppl 1):55-63; discussion 63-4. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11750253 (en)
http://linked.open...gy/drugbank/group	approved (en) investigational (en)
http://linked.open...drugbank/halfLife	10 hours (en)
http://linked.open...ugbank/indication	For the reduction of urinary obstruction and relief of associated manifestations (eg. sensation of incomplete bladder emptying or straining, urgency, interrupted or weak stream) in patients with symptomatic beningn prostatic hyperplasia. (en)
http://linked.open...bank/manufacturer	Bristol-Myers Squibb Co.
sameAs	Alfuzosin Alfuzosin
Title	Alfuzosin (en)
adms:identifier	http://linked.opendata.cz/resource/drugbank/drug/DB00346/identifier/chebi/51141 http://linked.opendata.cz/resource/drugbank/drug/DB00346/identifier/chemspider/2008 http://linked.opendata.cz/resource/drugbank/drug/DB00346/identifier/drugbank/DB00346 http://linked.opendata.cz/resource/drugbank/drug/DB00346/identifier/kegg-drug/D01692 http://linked.opendata.cz/resource/drugbank/drug/DB00346/identifier/national-drug-code-directory/0024-4200-30 http://linked.opendata.cz/resource/drugbank/drug/DB00346/identifier/pubchem-compound/2092 http://linked.opendata.cz/resource/drugbank/drug/DB00346/identifier/pubchem-substance/46508512 http://linked.opendata.cz/resource/drugbank/drug/DB00346/identifier/pharmgkb/PA164774795 http://linked.opendata.cz/resource/drugbank/drug/DB00346/identifier/wikipedia/Alfuzosin
http://linked.open...mechanismOfAction	Alfuzosin is a non-subtype specific alpha(1)-adrenergic blocking agent that exhibits selectivity for alpha(1)-adrenergic receptors in the lower urinary tract. Inhibition of these adrenoreceptors leads to the relaxation of smooth muscle in the bladder neck and prostate, resulting in the improvement in urine flow and a reduction in symptoms in benign prostate hyperplasia. Alfuzosin also inhibits the vasoconstrictor effect of circulating and locally released catecholamines (epinephrine and norepinephrine), resulting in peripheral vasodilation. (en)
http://linked.open...drugbank/packager	A-S Medication Solutions LLC Atlantic Biologicals Corporation Heartland Repack Services LLC Lake Erie Medical and Surgical Supply Murfreesboro Pharmaceutical Nursing Supply Nucare Pharmaceuticals Inc. Abbott Laboratories Ltd. Baxter International Inc. Hospira Inc.
http://linked.open...y/drugbank/patent	http://linked.opendata.cz/resource/drugbank/patent/2264250 http://linked.opendata.cz/resource/drugbank/patent/4661491 http://linked.opendata.cz/resource/drugbank/patent/6149940
http://linked.open...outeOfElimination	Following oral administration of 14C-labeled alfuzosin solution, the recovery of radioactivity after 7 days (expressed as a percentage of the administered dose) was 69% in feces and 24% in urine. (en)
http://linked.open.../drugbank/synonym	Alfuzosin (en) N-[3-[(4-amino-6,7-dimethoxy-quinazolin-2-yl)- methyl-amino]propyl] tetrahydrofuran- 2-carboxamide (en) Alfuzosina (en) Alfuzosine (en) Alfuzosinum (en) (±)-N-[3-[(4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino]propyl]tetrahydro-2-furamide (en)
http://linked.open...drugbank/toxicity	Side effects are dizziness (due to postural hypotension), upper respiratory tract infection, headache, and fatigue. (en)
http://linked.open...umeOfDistribution	* 3.2 L/kg [healthy male middle-aged volunteers] (en)
http://linked.open.../drug/hasAHFSCode	http://linked.opendata.cz/resource/AHFS/92-00-00
http://linked.open...k/foodInteraction	Take after a meal (always the same meal), product bioavailability is reduced when taken on an empty stomach. (en)
http://linked.open.../drugbank/mixture	Dutalfa
http://linked.open...nk/proteinBinding	82%-90% (en)
http://linked.open...ogy/drugbank/salt	(en)
http://linked.open...ynthesisReference	Mathias Scheer, "Alfuzosin tablets and synthesis." U.S. Patent US20060062845, issued March 23, 2006. (en)
http://linked.open...y/mesh/hasConcept	http://linked.opendata.cz/resource/mesh/concept/M0137486
foaf:page	http://www.drugs.com/cdi/alfuzosin.html http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/uro1685.shtml http://www.rxlist.com/cgi/generic/uroxatral.htm
http://linked.open...ugbank/IUPAC-Name	http://linked.opendata.cz/resource/drugbank/property/271B5CBA-363D-11E5-9242-09173F13E4C5
http://linked.open...gy/drugbank/InChI	http://linked.opendata.cz/resource/drugbank/property/271B5CC0-363D-11E5-9242-09173F13E4C5
http://linked.open...Molecular-Formula	http://linked.opendata.cz/resource/drugbank/property/271B5CBF-363D-11E5-9242-09173F13E4C5
http://linked.open.../Molecular-Weight	http://linked.opendata.cz/resource/drugbank/property/271B5CBC-363D-11E5-9242-09173F13E4C5
http://linked.open...noisotopic-Weight	http://linked.opendata.cz/resource/drugbank/property/271B5CBD-363D-11E5-9242-09173F13E4C5
http://linked.open...y/drugbank/SMILES	http://linked.opendata.cz/resource/drugbank/property/271B5CBE-363D-11E5-9242-09173F13E4C5
http://linked.open.../Water-Solubility	http://linked.opendata.cz/resource/drugbank/property/271B5CB8-363D-11E5-9242-09173F13E4C5
http://linked.open...ogy/drugbank/logP	http://linked.opendata.cz/resource/drugbank/property/271B5CB6-363D-11E5-9242-09173F13E4C5 http://linked.opendata.cz/resource/drugbank/property/271B5CB9-363D-11E5-9242-09173F13E4C5 http://linked.opendata.cz/resource/drugbank/property/271B5CD0-363D-11E5-9242-09173F13E4C5
http://linked.open...ogy/drugbank/logS	http://linked.opendata.cz/resource/drugbank/property/271B5CB7-363D-11E5-9242-09173F13E4C5
http://linked.open...l/drug/hasATCCode	Alfuzosin
http://linked.open...nd-Acceptor-Count	http://linked.opendata.cz/resource/drugbank/property/271B5CC6-363D-11E5-9242-09173F13E4C5
http://linked.open...-Bond-Donor-Count	http://linked.opendata.cz/resource/drugbank/property/271B5CC7-363D-11E5-9242-09173F13E4C5
http://linked.open...drugbank/InChIKey	http://linked.opendata.cz/resource/drugbank/property/271B5CC1-363D-11E5-9242-09173F13E4C5
http://linked.open...urface-Area--PSA-	http://linked.opendata.cz/resource/drugbank/property/271B5CC2-363D-11E5-9242-09173F13E4C5
http://linked.open...nk/Polarizability	http://linked.opendata.cz/resource/drugbank/property/271B5CC4-363D-11E5-9242-09173F13E4C5
http://linked.open...bank/Refractivity	http://linked.opendata.cz/resource/drugbank/property/271B5CC3-363D-11E5-9242-09173F13E4C5
http://linked.open...atable-Bond-Count	http://linked.opendata.cz/resource/drugbank/property/271B5CC5-363D-11E5-9242-09173F13E4C5
http://linked.open...ugbank/absorption	Absorption is 50% lower under fasting conditions (en)
http://linked.open.../affectedOrganism	Humans and other mammals (en)
http://linked.open...casRegistryNumber	81403-80-7 (en)
http://linked.open...drugbank/category	(en)
http://linked.open...gbank/containedIn	Amoxil 200 mg/5ml Suspension 100ml Bottle Ondansetron odt 4 mg tablet
http://linked.open...k/Bioavailability	http://linked.opendata.cz/resource/drugbank/property/271B5CCC-363D-11E5-9242-09173F13E4C5
http://linked.open...bank/Ghose-Filter	http://linked.opendata.cz/resource/drugbank/property/271B5CCE-363D-11E5-9242-09173F13E4C5
http://linked.open...nk/MDDR-Like-Rule	http://linked.opendata.cz/resource/drugbank/property/271B5CCF-363D-11E5-9242-09173F13E4C5
http://linked.open...k/Number-of-Rings	http://linked.opendata.cz/resource/drugbank/property/271B5CCB-363D-11E5-9242-09173F13E4C5
http://linked.open...siological-Charge	http://linked.opendata.cz/resource/drugbank/property/271B5CCA-363D-11E5-9242-09173F13E4C5
http://linked.open...bank/Rule-of-Five	http://linked.opendata.cz/resource/drugbank/property/271B5CCD-363D-11E5-9242-09173F13E4C5
http://linked.open...tional-IUPAC-Name	http://linked.opendata.cz/resource/drugbank/property/271B5CBB-363D-11E5-9242-09173F13E4C5
http://linked.open...strongest-acidic-	http://linked.opendata.cz/resource/drugbank/property/271B5CC8-363D-11E5-9242-09173F13E4C5
http://linked.open...-strongest-basic-	http://linked.opendata.cz/resource/drugbank/property/271B5CC9-363D-11E5-9242-09173F13E4C5

Faceted Search & Find service v1.16.118 as of Jun 21 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 32 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software